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allergenic glove', since such gloves still contain la tex and may 
not be used by latex-sensitised individuals, and will not 
prevent the developmen t of latex allergies in _those as yeL 
unaffected workers. 
It is essen tial that the problem of latex allergy in hospi tals 
should be addressed as a matter of urgency by the authorities 
and hospital administration in order to contair. the problem. 
Although the provision of a c0mpletely powder-free 
environment may be initially more expensive, the long-term 
savings in terms of loss of staff, morbidity, loss of productivity, 
and litigation far outweigh the short-term gains of purchasing 
cheap quality powdered gloves. 
Professor eil White performed occupational assessments on 
several of the patients. The authors acknowledge the financial 
support of Regent Medical (UK) and Laboratory Specialities (South 
Africa), and permission from the Medical Superintendent of Groote 
Schuur Hospital to publish this report. 
Dr M Isaacs of the Groote Schuur Hospital Biostatistics 
Department performed the statistical analysis of the data. 
References 
1. Nu tter A. Contact urticaria to rubber. Br} DemEOto/1979; 191: 597-598. 
2. Marais G, Fletcher j, Potter PC. hr vivo and in vitro diagnosis of latex allergy at Groote Schuur 
Hospital. S Afr Med j 1997; 57, 1004-1008. 
3. Turjanmaa K. Incidence of immediate allergy to la tex gloves in hospital personneL Contact 
Dennatology 1987; 17:270-275. 
-l. Lagier F, Vervloet D, Lhermet I, Pagan D, Charpin D. Prevalence of latex a1lergy among 
operating room nurses. f Allergy Clirz lmmunof 1992; 319: 319-322. 
5. Arellano R, Bradley J, Sussman G. Prevalence of latex sensitization among hospital 
physicians occupationally exposed to latex gloves. Aflaestltesiology 1992; 77: 905-908. 
6. Liss GM, Sussman GL, Dent K, eta!. Latex allergy: Epidemiological study of 1 351 hospital 
workers. Occup Environ Med 1997; 54: 335-342. 
7 Brathwaite , Motala C, Toerien A, Schinkel M, Potter PC Latex allergy- the Red Cross 
Children's Hospi tal experience (Scientific letter). 5 Afr Med I 2001; 91:750-751 (this issue). 
8. De Beer C, Cilliers J, Kosheva 0 , Crombie I, Truter E, Potter PC. Latex gloves: More harm 
than good? Medical Technology SA 1999; 13: 282-288. 
9. Stewart R, Wadee A, Potter PC, Duse A. Latex allergy in laboratory staff at the johannesburg 
General Hospital (Abstract). Ailsa Congress, johannesburg 1999. 
10. Blanco C. Cavillo T, Castillo R, Quiral te j , Cuevas M. La tex allergy: Qinjcal features and 
cross-reactivity with fruits. Ann Allergy 1994; 73: 309-314. 
Accepted 4 May 2001. 
HIGH-DOSE IMMUNOSUPPR ES-
SIVE THERAPY IN GENERALISED 
MYASTHENIA GRAVIS- A 2-YEAR 
FOLLOW-UP STUDY 
J M Heckmann, E B LeePan, R W Eastman 
Background. Immunosuppressive (IS) therapy is increasingly 
advocated in the treatment of myasthenia gra vis (MG). This 
study assessed whether early 'high-dose' IS therapy in new 
patients with generalised MG (GMG) altered the outcome 
and reduced the morbidity of GMG. 
M ethods. Patients with GMG were treated with 'high-dose' 
IS therapy (prednisone S 1 mg/ kg, azathioprine 2- 3 
mg/ kg) and followed up for 2 years. Prednisone and 
azathioprine were ini tiated on diagnosis. Outcome 
measures were compared with those of controls previously 
treated at our clinic wi th ' low-dose' IS therapy. The primary 
outcome measure was the number of patients in remission 
at 1 and 2 years. Secondar y outcomes included the MG 
scores (MGS) after 1 and 2 years, as well as the number of 
plasma exchanges (P / E), hosp ital and intensive care unit 
(ICU) admi sions required for decompensated MG. 
Findings. At 1 and 2 years there were ignificant 
improvements in the MGS of patients treated with 'high-
dose' IS therapy compared wi th those of controls; 50% of 
these patients were in remission after 2 year comp ared 
wi th less than 16% of controls. The number of hospital and 
ICU admissions had also dropped significantly in the .fi rst 
year of patients receiving 'high-do e' IS treatment. 
Conclusion. Early 'high-dose' IS therapy using azathioprine 
and prednisone in GMG resul ted in a significant increase in 
the number of patients in remis ion and reduced morbidi ty 
at 1 and 2 years. 
5 Afr Med I 2001; 91, 765-770. 
Myasthenia gravis (MG) is an au toimmune disorder mediated 
by immunoglobulin G (IgG) antibodies to the muscle 
acetylcholine receptor (AChR).' This results in a reduction in 
the n umber of effective AChRs, impaired neuromuscular 
transmission, and therefore clinically in fatiguable muscle 
weakness.' Autoantibodies against the AChR can be detected in 
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the sera of 85 - 90% of patients with generalised weakness.' 
Reduction in the number of functional end-plate receptors 
resulting from the deleterious effects of the AChR antibodies3 is 
due to complement-mediated lysis) increased receptor 
degradation/ and pharmacological block• of the AChR. Plasma 
exchange (P /E), which lowers the serum level of antibodies, 
produces clinical improvement.' The factors that trigger the 
initial loss of self-tolerance and therefore the autoimmune 
response, are not known. 
The world-wide prevalence of MG has been estimated to be 
5- 10 per 100 000." Groote Schuur Hospital treats 
approximately 12 - 18 new cases per year, referred mainly from 
the Western Cape. Patients with generalised MG (GMG) and 
positive AChR antibodies can be classified into three main 
subgroups." About 60% present with symptoms from puberty 
to age 40 years (early-onset MG (EOMG)), and the majority of 
this group show hyperplasia of the thymic medulla•·• for which 
a thymectomy is recommended. Secondly, less than 20% 
present with late-onset disease (> 40 years), and thirdly about 
10% have an associated thymoma!·10 A further 
10- 15% of patients with GMG will have no AChR antibodies 
detectable in their sera (seronegative MG)!·10 However, 
pathogenic antibodies have been implicated in these patients, 
probably binding to the neuromuscular junction a t a site 
distinct from the AChR," and these patients also respond to 
P /E.' 
Before 1996 there was no standard protocol in our clinic as to 
how to treat GMG; the mainstay of treatment was the 
anticholinesterases. Prednisone, the principal 
immunosuppressant, was used sparingly. It was our 
impression that very few of our patients were going into 
remission, and that many of them still had chronic active 
disease, even requiring hospital and intensive care unit (ICU) 
admission, many years after the initial presentation. 
Before corticosteroids were introduced, GMG was treated 
with anticholinesterases as well as thymectomy in appropriate 
(EOMG and thymoma) patients; the disease mortality rate was 
30% and ultimately only 13% of patients went into remission.'' 
Between 1960 and 1980 corticosteroids were used to treat GMG 
and the mortality rate started to fall (14%), but the remission 
rate was essentially unchanged (6%, mean follow-up 12 years, 
N = 476). '2 
Azathioprine had been used in Germany since 1969 in doses 
ranging from 2 to 2.5 mg/kg and found to be effective as a 
single treatment in GMG.13·" Over recent years azathioprine has 
been used as IS therapy in GMG and, based largely on 
retrospective uncontrolled studies, the usefulness of high-dose 
azathioprine (2- 3 mg/ kg) as a steroid-sparing agent, is 
generally advised in texts."·15 In 1993 a randomised non-blind 
trial of azathioprine versus prednisone after 4 months of initial 
prednisone, showed more treatment failures in the prednisone 
group. •• There was no difference in the functional outcome 
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between the two treatment groups, but more than one-third of 
the patients had a prolonged disease duration before the study, 
which may have influenced their immunosuppressive 
responsiveness. In practice, patients are often reluctantly put 
onto low doses of azathioprine as an add-on second-line IS 
agent when prednisone has failed, often many years after 
symptom onset. This reluctance may stem from the delay in the 
therapeutic response to azathioprine which is only evident 
after a few months, whereas with prednisone it is much sooner. 
A prospective study was initiated to determine whether high 
d oses of IS drugs (prednisone plus azathioprine) early in the 
course of GMG would influence the clinical outcome and 
morbidity over a 2-year treatment period. 
P ATIENTS AND METHO DS 
The diagnosis of MG was based on clinical evidence of 
fatiguable weakness, supported by a positive anticholinesterase 
test (edrophonium chloride) and/ or an AChR antibody assay. 
The anti-AChR antibody radio-immunoassay performed by the 
University of Cape Town clinical immunology laboratory, is 
dependent on AChRs extracted from a human cell line (TE671 
cells) and labelling it with 125I-labelled a-bungarotoxin.' 
Repetitive nerve stimulation was performed in selected 
patients. 
The patients were objectively evaluated for fatiguable 
weakness by scoring 13 categories including ocular and bulbar 
muscles, vital capacity as a measure of respiratory muscle 
function, and proximal upper and lower limb fatiguability. The 
MG score (MGS) was adapted from that published by Tindall et 
a/. 17 (Table I). 
The primary outcome measure was the number of patients in 
remission at 1 and 2 years. An MGS of 0 was considered to be 
equivalent to clinical remission and, as the patients were also 
asymptomatic, they were no longer taking anticholinesterases. 
Secondary outcomes included the MGS after 1 and 2 years, as 
well as the number of P / E, hospital and ICU admissions 
required for decompensated MG. Hospitalisation at diagnosis 
was not included. All the patients presenting with early, active 
GMG from October 1996 were entered into the study at the 
time of diagnosis. The data in this paper only pertain to those 
patients entering the study within an arbitrary time limit of 2 
years from symptom onset. The patients were scored at study 
entry as well as at follow-up visits. 
Outcome measures were compared with historical controls, 
namely patients previously treated at our clinic with IS therapy 
for similar durations. Only those who had been initiated on IS 
therapy ('low-dose') within 2 years of symptom onset were 
included. 'Low-dose' refers most often to prednisone alone or 
in some cases to a low-dose prednisone/ azathioprine 
combination. The records of patients attending the MG clinic 
from 1986 to 1996 provided control data on the number of 
I 
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Table I. Quantified MG score (MGS) adapted from Tindall et al." ) 
Grade of weakness 
Test items None (0) Mild (1) Moderate (2) Severe (3) 
1. Diplopia on lateral gaze (s) > 60 > 10 -60 > 1 - 10 Spontaneous 
diplopia 
2. Ptosis (upgaze) (s) > 60 > 10 - 60 > 1 - 10 Spontaneous 
3. Facial muscles Normal Mild weakness on lid Incomplete lid closure o mimic 
closure; snarl expressions 
4. Chewing Normal Fatigue after solids Only soft foods Gastric tube 
5. Swallowing Normal Fatigue after normal Incomplete palatal Gastric tube 
foods closure; nasal speech 
6. Head lifting(s) * > 120 > 30 - 120 > 0 - 30 0 
7. Outstretching right arm (s)t > 180 . > 90 -180 >10 - 90 < 10 
8. Outstretching left arm (s)t 
9. VC (litres) 
Male > 3.5 > 2.5 - 3.5 > 1.5- 2.5 < 1.5 
Female > 2.5 > 1.8 -2.5 > 1.2 -1.8 < 1.2 
10. Elevating right leg (s)+ > 100 > 30 - 100 > 0 - 30 0 
11. Elevating left leg (s):l: 
12. Right-hand grip (MRC) 5/5 4/5 3 / 5 1 - 2/5 
13. Left-hand grip (MRC) 
VC : vital capacity; MRC : Medical Research Council motorgrading score. 
• Head lifting is performed with the patient lying supine and lifting th~ head at 45° off the bed. 
t Outstretching left and right arms is performed with the patient lifting the arms 90• to the front; counting is terminated when sagging of the shoulders o r downward drifting of the 
arms occur. 
:j: Elevating right and left legs is performed with the patient lying supine and lifting them independently to 45•. 
remissions at 1 and 2 years of 'low-dose' IS therapy, the 
number of PIE, and hospital and ICU admlssions reqillred for 
decompensa ted MG. A small proportion of this control group 
had been initiated on treatment between 1994 - 1995 (prior to 
this study), and could be scored using the MGS at 1 and 2 years 
of therapy, for comparison. 
Patients were classified as defaulters if, in thP preceding 6 
months, they had discontinued their treatmen t for 2 weeks or 
more. 
Treatment protocol 
Once the diagnosis of GMG was confirmed, anticholinesterases 
and IS therapy were started . A test dose of azathioprine 
(50 mg) was given to assess tolerance. The dose was increased 
to approximately 1 - 1.5 mg/~:g and the whi te cell count (WCC) 
was moni tored fortnightly for 4 weeks. If the wee fell below 
3 x HY' / 1, or the lymphocytes below 0.8 x 1CY' / 1, azathioprine was 
discontinued for a few d ays and re-introd uced at a slightly 
lower dose." If the blood count was stable, azathioprine was 
increased to a maintenance level of 2.5 - 3 mg/ kg and blood 
counts were checked a t intervals. 
Prednisone was s tarted a t a low dose (15 - 20 mg) with 5 mg 
increments every 1 - 4 weeks until the patient was either 
asymptomatic, side-effects had intervened, or a dose of 
1 mg/kg was reached. If the patient became asymptomatic, 
anticholinesterases were reduced and stopped, prednisone was 
slowly withdrawn and azathioprine was continued on the 
lowest dose that maintained the blood count at the minimum 
safe levels. (In those patients who received alternate-day 
prednisone throughout the treatment period, only 50% of their 
mean dose was used for the calculation.) 
As previously, thymectomies were performed in tho e 
patients wi th EOMG and suspected thymoma. 
Statistical analysis 
The MGS, mean drug doses, duration of symptoms and 
duration of exposure to IS therapy at time of evaluation 
between the two groups were compared using the Student's 
t-test (I-tailed). Chi-squared analy es (df = 1) were performed 
for the primary and secondary outcome comparisons. A 
P-value > 0.05 was considered not significant ( S). 
R ESULTS 
We present the 1- and 2-year follow-up results of patients 
exposed to 'high-dose', and controls exposed to 'low-dose', IS 
L'lerapy for similar periods from time of symptom onset. The 
types of MG and age of onset in both the study and control 
groups were comparable (Tables II and Ill). Thymectomies 
were performed in all EOMG controls at a mean of 1.38 
(SD ± 1.22) years from s ymptom onset, and in 7 of the 'high-
dose' group at 1.73 (SD ± 1.37) years (P = NS). 
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the sera of 85 - 90% of patients with generalised weakness-' 
Reduction in the number of functional end-plate receptors 
resulting from the deleterious effects of the AChR antibodies' is 
due to complement-mediated lysis,' increased receptor 
degradation,' and pharmacological block• of the AChR. Plasma 
exchange (P / E), which lowers the serum level of antibodies, 
produces clinical improvement.7 The factors that trigger the 
initial loss of self-tolerance and therefore the autoimmune 
response, are not known. 
The world-wide prevalence of MG has been estimated to be 
5 - 10 per 100 000.8 Groote Schuur Hospital treats 
approximately 12-18 new cases per year, referred mainly from 
the Western Cape. Patients with generalised MG (GMG) and 
positive AChR antibodies can be classified into three main 
subgroups. About 60% present with symptoms from puberty 
to age 40 years (early-onset MG (EOMG)), and the majority of 
this group show hyperplasia of the thymic medulla '·9 for which 
a thymectomy is recommended . Secondly, less than 20% 
present with late-onset disease (> 40 years), and thirdly about 
10% have an as ociated thymoma.•·•• A further 
10 - 15% of patients with GMG will have no AChR antibodies 
detectable in their sera (seronegative MG)! ·'0 However, 
pathogenic antibodies have been implicated in these patients, 
probably binding to the neuromuscular junction at a site 
distinct from the AChR,11 and these patients also respond to 
P / E.' 
Before 1996 there was no standard protocol in our clinic as to 
how to treat GMG; the mainstay of treatment was the 
anticholinesterases. Prednisone, the principal 
immunosuppressant, was used sparingly. It was our 
impression that very few of our patients were going into 
remission, and that many of them still had chronic ac ti ve 
disease, even requiring hospi tal and intensive care unit (ICU) 
admission, many years after the initial presentation. 
Before cortico teroids were introduced, GMG was treated 
with anticholinesterases as well as thymectomy in appropriate 
(EOMG and thymoma) patients; the disease mortality rate was 
30% and ultimately only 13% of patients went into remission." 
Between 1960 and 1980 corticosteroids were used to treat GMG 
and the mortality rate started to fall (14%), but the remi sion 
rate was essentially unchanged (6%, mean follow-up 12 years, 
= 476) _12 
Azathioprine had been used in Germany since 1969 in doses 
ranging from 2 to 2.5 mg/ kg and found to be effective as a 
single treatment in GMG."·" Over recent years azathioprine has 
been used as IS therapy in GMG and, based largely on 
retrospective uncontrolled studies, the usefulness of high-dose 
azathioprine (2 - 3 mg/ kg) as a steroid-sparing agent, is 
generally advised in texts.'·" In 1993 a randomised non-blind 
trial of azathioprine versus prednisone after 4 months of initial 
prednisone, showed more treatment failures in the prednisone 
group. •• There was no difference in the functional outcome 
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between the two treatment groups, but more than one-third of 
the patients had a prolonged disease duration before the study, 
which may have influenced their immunosuppressive 
responsiveness. In practice, patients are often reluctantly put 
onto low doses of azathioprine as an add-on second-line IS 
agent when prednisone has failed, often many years after 
symptom onset. This reluctance may stem from the delay in the 
therapeutic response to azathioprine which is only evident 
after a few months, whereas wi th prednisone it is m uch sooner. 
A prospective study was initia ted to determine whether high 
doses of IS drugs (prednisone plus azathioprine) early in the 
course of GMG would influence the clinical outcome and 
morbidity over a 2-year treatment period. 
p ATIENTS A N D M ETHODS 
The diagnosis of MG was based on clinical evidence of 
fatiguable weakness, supported by a positive anticholinesterase 
test (edrophonium chloride) and / or an AChR antibody assay. 
The anti-AChR antibody radio-immunoassay performed by the 
University of Cape Town clinical immunology laboratory, is 
dependent on AChRs extracted from a human cell line (TE671 
cells) and labelling it with '"'1-labelled a-bungarotoxin.' 
Repetitive nerve stimulation was performed in selected 
patients. 
The patients were objectively evaluated for fatiguable 
weakness by scoring 13 categories including ocular and bulbar 
muscles, vital capacity as a measure of respiratory muscle 
function, and proximal upper and lower limb fatiguability. The 
MG score (MGS) was adapted from that published by Tindall et 
a/. 17 (Table I) . 
The primary outcome measure was the number of patients in 
remission at 1 and 2 years. An MGS of 0 wa con idered to be 
equivalent to clinical remission and, as the patients were also 
asymptomatic, they were no longer taking anticholinesterases. 
Secondary ou tcomes included the MGS after 1 and 2 years, as 
well as the number of P / E, hospital and ICU admis ions 
required for decompensated MG. Hospitalisation at diagnosis 
was not included. All the patients presenting with early, active 
GMG from October 1996 were entered into the study at the 
time of diagnosis. The data in this paper only pertain to those 
patients entering the study within an arbitrary time limit of 2 
years from symptom onset. The patient were scored at study 
entry as well as at follow-up visits. 
Outcome measures were compared with historical controls, 
namely patients previously treated at our clinic with IS therapy 
for similar durations. Only those who had been initiated on IS 
therapy ('low-dose') within 2 years of symptom onset were 
included. 'Low-dose' refers most often to prednisone alone or 
in some cases to a low-dose prednisone/aza thioprine 
combination. The records of patients a ttending the MG clinic 
from 19 6 to 1996 provided control data on the number of 
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Table I. Quantified MG score (MGS) adapted from Tmdall eta/.'') 
Grade of weakness 
Test items one (0) Mild (1) Moderate (2) Severe (3) 
1. Diplopia on lateral gaze (s) >60 > 10-60 > 1-10 Spontaneous 
diplopia 
2. Ptosis (upgaze) (s) > 60 > 10- 60 > 1 -10 Spontaneous 
3. Facial muscles ormal Mild weakness on lid Incomplete lid closure No mimic 
closure; snar] expressions 
4. Chewing ormal Fatigue after solids Only soft foods Gastric tube 
5. Swallowing ormal Fatigue after normal Incomplete palatal Gastric tube 
foods closure; nasal speech 
6. Head lifting(s) * > 120 > 30-120 > 0-30 0 
7. Outstretching right arm (s)t > 180 ' > 90-180 > 10- 90 < 10 
8. Outstretching left arm (s)t 
9. VC (litres) 
Male > 3.5 > 2.5-3.5 > 1.5-2.5 <1.5 
Female > 2.5 >L -2.5 > 1.2-1.8 < 1.2 
10. Elevating right leg (s)i > 100 > 30-100 > 0-30 0 
11. Elevating left leg (s)i 
12. Right-hand grip (MRC) 5/5 4/ 5 3/5 1 - 2/5 
13. Left-hand grip (MRC) 
~C = vitalcapacity; MRC = Medical Research Council motorgrading score. 
t Head liftm~ ts perfonned with the patient lying supine and lifting the head at -15• off the bed. 
Oulstretching left and nght arms 15 perfonned with the patient lifting the arms 90" to the front; counting is terminated when sagging of the shoulders or downward drifting of the 
armsocCUL 
t Elevating right and left legs is performed with the patient lying supine and lifting them independently to 45". 
remissions at 1 and 2 years of ' low-dose' IS therapy, the 
number of P / E, and hospital and JCU admissions required for 
decompensated MG. A small proportion of this control group 
had been initiated on treatment between 1994- 1995 (prior to 
this study), and could be scored using the MGS at 1 and 2 years 
of therapy, for comparison. 
Patients were classified as defaulters if, in the ?receding 6 
months, they had discontinued their treatment for 2 weeks or 
more. 
Treatment protocol 
Once the diagnosis of GMG was confirmed, anticholinestera e 
and IS therapy were started. A test dose of azathioprine 
(50 mg) was given to assess tolerance. The dose was increased 
to approximately 1 - 1.5 mg/ kf, and the white cell count (WCC) 
wa monitored fortnightly for 4 weeks. If the wee fell below 
3 x 10"" / 1, or the lymphocytes below 0. x 10" / I, azathioprine was 
discontinued for a few days and re-introduced at a slightly 
lower dose." If the blood count wa stable, azathioprine wa 
increased to a maintenance level of 2.5 - 3 mg/ kg and blood 
counts were checked at intervals. 
Prednisone was started at a low dose (15 - 20 mg) with 5 mg 
increments every 1 - 4 weeks until the pa tient was either 
asymptomatic, side-effects had intervened, or a dose of 
1 mg/ kg was reached . If the patient became asymptomatic, 
anticholine terases were reduced and stopped, prednisone was 
slowly withdrawn and azathioprine was continued on the 
lowest dose that maintained the blood count at the minimum 
safe levels. (ln those patients who received alternate-day 
prednisone throughout the treatment period, only 50% of their 
mean dose was used for the calculation.) 
A previously, thymectomies were performed in tho e 
patients with EOMG and uspected thymoma. 
Statistical analysis 
The MGS, mean drug do es, duration of symptoms and 
duration of exposure to IS therapy at time of evaluation 
between the two groups were compared using the Student' 
/-test (!-tailed}. Chi- quared analyses (df = 1) were performed 
for the primary and secondary outcome comparisons. A 
P-val ue > 0.05 was considered not significant ( S). 
R ESULTS 
We present the 1- and 2-year follow-up results of patients 
expo ed to 'high-dose', and controls exposed to 'low-do e', IS 
therapy for similar period from time of symptom onset. The 
types of MG and age of onset in both the study and control 
groups were comparable (Tables II and Ill) . Thymectomies 
were performed in all EOMG controls a t a mean of 1.38 
(SD ± 1.22) years from symptom onset, and in 7 of the 'high-
dose' group at 1.73 (SD ± 1.37) year (P = S). 
the sera of 85- 90% of patients with generalised weakness.' 
Reduction in the number of functional end-plate receptors 
resulting from the deleterious effects of the AChR antibodies' is 
due to complement-mediated lysis,' increased receptor 
degradation,' and pharmacological block• of the AChR. Plasma 
exchange (P /E), which lowers the serum level of antibodies, 
produces clinical improvem ent.' The factors that trigger the 
initial loss of self-tolerance and therefore the autoimmune 
response, are not known. 
The world-wide prevalence of MG has been estimated to be 
5- 10 per 100 000.8 Groote Schuur Hospital treats 
approximately 12- 18 new cases per year, referred mainly from 
the Westem Cape. Patients with generalised MG (GMG) and 
p ositive AChR antiboclies can be classified into three main 
subgroups.' About 60% present with symptoms from puberty 
to age 40 years (early-onset MG (EOMG)), and the majority of 
this group show hyperplasia of the thymic medulla 1·' for which 
a thymectomy is recommended. Secondly, less than 20% 
present wi th late-onset disease (> 40 years), and thirdly about 
10% have an associated thymoma.'·10 A further 
10- 15% of patients with GMG will have no AChR antiboclies 
detectable in their sera (seronega tive MG).'·10 However, 
pathogenic antibodies have been implicated in these patients, 
probably bincling to the neuromuscular junction at a site 
distinct from the AChR, 11 and these patients also respond to 
P /E. 1 
Before 1996 there was no standard protocol in our clinic as to 
how to trea t GMG; the mainstay o f treatment was the 
anticholinesterases. Prednisone, the principal 
immunosuppressant, was used sparingly. It was our 
impression that very few of our p atients were going into 
remission , and that many of them still had chronic active 
disease, even requiring h ospital and intensive care unit (JCU) 
admission, many years after the initial presentation. 
Before corticosteroids were introduced, GMG was treated 
with anticholinesterases as well as thymectomy in appropriate 
(EOMG and thymoma) patients; the clisease mortality rate was 
30% and ultimately only 13% of patients went into rernissionY 
Between 1960 and 1980 corticosteroids were used to treat GMG 
and the mortality rate started to fall (14%), but the remission 
rate was e sentialiy unchanged (6%, mean follow-up 12 years, 
N = 476). 11 
Azathioprine had been used in Germany since 1969 in doses 
ranging from 2 to 2.5 mg/ kg and found to be effective as a 
single treatment in GMGn ·14 Over recent years azathioprine has 
been used as IS therapy in GMG and, based largely on 
retrospective uncontrolled studies, the usefulness of high-dose 
azathioprine (2 - 3 mg/ kg) as a steroid-sparing agent, is 
generally advised in texts.'·15 In 1993 a randomised non-blind 
trial of azathioprine versus prednisone after 4 months of initial 
prednisone, showed more treatment failures in the prednisone 
group.16 There was no difference in the functional outcome 
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between the two treatment groups, but more than one-third of 
the patients had a prolonged disease duration before the study, 
which may have influenced their immunosuppressive 
responsiveness. In practice, patients are often reluctantly put 
onto low doses of azathioprine as an add-on second-line IS 
agent when prednisone has failed, often many years after 
symptom onset. This reluctance may stem from the delay in the 
therapeutic response to azathioprine which is only evident 
after a few months, whereas with prednisone it is much sooner. 
A prospective study was initiated to determine whether high 
doses of IS drugs (prednisone plus azathioprine) early in the 
course of GMG would influence the clinical outcome and 
morbidity over a 2-year treatment period. 
pATIENTS AND METHODS 
The cliagnosis of MG was based on clinical evidence of 
fatiguable weakness, supported by a positive anticholinesterase 
test (edrophonium chloride) and / or an AChR antibody assay. 
The anti-AChR antibody raclio-irrununoassay performed by the 
University of Cape Town clinical immunology laboratory, is 
dependent on AChRs extracted from a human cell line (TE671 
cells) and labelling it with 1251-labelled a -bungarotoxin.2 
Repetitive nerve stimulati0n was performed in selected 
patients. 
The patients were objectively evaluated for fatiguable 
weakness by scoring 13 categories including ocular and bulbar 
muscles, vital capacity as a measure of respiratory muscle 
function, and proximal upper and lower limb fatiguability. The 
MG score (MGS) was adapted from that published by Tindall et 
af.l' (Table I). 
The primary outcome measure was the number of patients in 
remission at 1 and 2 years. An MGS of 0 was considered to be 
equivalent to clinical remission and, as the patients were also 
asymptomatic, they were no longer taking anticholinesterase . 
Secondary outcomes included the MGS after 1 and 2 years, as 
well as the number of P / E, hospital and ICU admissions 
required for decompensated MG. Hospitalisation at diagnosis 
was not included. All the patients presenting wi th early, active 
GMG from October 1996 were entered into the s tudy at the 
time of diagnosis. The data in this paper only pertain to those 
patients entering the study within an arbitrary time limit of 2 
years from symptom onset. The patients were scored at study 
entry as well as at follow-up visits. 
Outcome measures were compared with historical controls, 
namely patients previously treated at our clinic with IS therapy 
for similar durations. Only those who had been initiated on IS 
therapy (' low-dose') wi thin 2 years of symptom onset were 
included. 'Low-dose' refers most often to prednisone alone or 
in some cases to a low-dose prednisone/ azathioprine 
combination. The records of patients a ttending the MG clinic 
from 1986 to 1996 provided control data on the number of 
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Table I . Quantified MG score (MGS) adapted from Tindall et al.") 
Grade of weakness 
Test items one (0) Mild (1) Moderate (2) Severe (3) 
1. Diplopia on lateral gaze (s) > 60 > 10-60 > 1 - 10 Spontaneous 
diplopia 
2. Ptosis (upgaze) (s) > 60 > 10 - 60 > 1 - 10 Spontaneous 
3. Facial muscles ormal Mild weakness on lid Incomplete lid closure o mimic 
closure; snarl expressions 
4. Chewing ormal Fatigue after solids Only soft foods Gastric tube 
5. Swallowing Normal Fatigue after normal Incomplete palatal Gastric tube 
foods closure; nasal speech 
6. Head lifting(s) • > 120 > 30- 120 > 0-30 0 
7. Outstretching right arm (s)t > 180 . > 90 - 180 > 10 - 90 < 10· 
8. Outstretching left arm (s)t 
9. VC (litres) 
Male > 3.5 > 2.5-3.5 > 1.5 -2.5 <1.5 
Female > 2.5 > 1.8- 2.5 > 1.2- 1.8 < 1.2 
10. Elevating right leg (s):J: > 100 > 30 · 100 > 0-30 0 
11. Elevating left leg (s):J: 
12. Right-hand grip (MRC) 5/5 4/ 5 3/5 1-2/5 
13. Left-hand grip (MRC) 
VC = vital capacity; MRC = Medical Research Council motorgrading score. 
• Head lifting is performed with the patient lying supine and lifting the head at 45" off the bed. 
t Outstretching left and right arms is performed with the patient lifting the arms 90" to the front; counting is tenninated when sagging of the shoulders or downward drifting of the 
arms occur. 
:f: Elevating right and left legs is performed with the patient lying supine and lifting them independently to 45". 
remissions at 1 and 2 years of 'low-dose' IS therapy, the 
number of P /E, and hospital and JCU admissions requiled for 
decompensated MG. A small proportion of tills control group 
had been irutiated on treatment between 1994- 1995 (prior to 
this s tudy), and could be scored using the MGS at 1 and 2 years 
of therapy, for comparison. 
Patients were classified as defaulters if, in the preceding 6 
months, they had discontinued their treatment for 2 weeks or 
more. 
Treatment protocol 
Once the diagnosis of GMG was confirmed, anticholinesterases 
and IS therapy were started. A test dose of azatruoprine 
(50 mg) was given to assess tolerance. The dose was increased 
to approxilnately 1 - 1.5 mg/kr; and the white cell count (Wee) 
was monitored fortnightly for 4 weeks. If the wee fell below 
3 x 1()-9 / I, or the lymphocytes below 0.8 x lfr9 / I, azatruoprine was 
discontinued for a few days and re-introduced at a slightly 
lower dose. " If the blood count was stable, azatruoprine was 
increased to a maintenance level of 2.5 - 3 mg/kg and blood 
counts were checked at intervals. 
Prednisone was started at a low dose (15 - 20 mg) with 5 mg 
increments every 1 - 4 weeks until the patient was either 
asymptomatic, side-effects had intervened, or a dose of 
1 mg/kg was reached. If the patient became asymptomatic, 
anticholinesterases were reduced and stopped, prednisone was 
slowly withdrawn and azatruoprine wa continued on the 
lowest dose that maintained the blood count at the minimum 
safe levels. (In those patients who received alternate-day 
prednisone throughout the treatment period, only 50% of theil 
mean dose was used for the calculation.) 
As previously, thymectomies were performed in those 
patients with EOMG and suspected thymoma. 
Statistical analysis 
The MGS, mean drug doses, duration of symptoms and 
duration of exposure to IS therapy at time of evaluation 
between the two groups were compared u ing the Student's 
He t (! -tailed). Chi-squared analy e (df = 1) were performed 
for the primary and secondary outcome comparisons. A 
P-vaJue > 0.05 was considered not significant ( S). 
RESULTS 
We present the 1- and 2-year follow-up results of patients 
exposed to 'high-dose', and control exposed to ' low-dose', IS 
therapy for similar periods from time of symptom onset. The 
types of MG and age of onset in both the study and control 
groups were comparable (Tables ll and Ill). Thymectomies 
were performed in all EOMG controls at a mean of 1.38 
(SD ± 1.22) years from symptom onset, and in 7 of the 'high-
dose' group at 1.73 (SD ± 1.37) years (P = S). 
I lim 






Mean time (yrs) between onset of 
symptoms and IS therapy (SD) 
MGS at entry (SD) 
MGS at 1 year (SD) 
Remissions(%) 
'High-dose' 






15.27 ( 6.30) 
1.79 (2.57) 
53% (CI ± 23.8) 
Controls 








16% (CI ± 29.8) 
P-value+ 




IS = immunosuppressive; MGS = MG score; SO = standard deviation from sample mean; 0 = 95o/o confidence interval. 
• All subjects received IS therapy \\~thin 2 years of symptom onset. Age at symptom onset was comparable between high-dose patients and controls (P = NS}. 
t Controls were evaluated after a mean of 0.97 (SO 0.08} years of low-dose IS therapy. 
:j: P-value oft-test (!-tailed}. Chi-test (PX'} was performed with df = 1. · 
Table III. 'High-dose' immunosuppressive therapy versus 'low-dose' therapy in controls evaluated after 2 years• 
High dose 
(N = 10) 
Type of MG (%) 
EOMG 60% (6) 
Thymoma 10% (1) 
Late-onset MG 20% (1) 
Seronegative 10% (1) 
Mean time (yrs) between onset of 0.76 (0.61) 
symptoms and IS therapy (SD) 
MGS at entry (SD) 16.30 (5.77) 
MGS at 2 years (SD) 1.22 (1.48) 










13%§ (CI = 23.4) 
P-value 




IS = immunosuppressive; MGS = MG score; SD = standard deviation from sample mean; Cl = 95% confidence interval. • 
• All subjects received IS therapy within 2 years of symptom onset. Age at symptom onset was comparable between high-dose patients and controls {P = 0.34). 
t P·value of l·test (!-tailed}. Chi-test {PX'} was performed with df = 1. 
:j: Controls were evaluated after a mean of 2.66 (SO 0.52, range 2 - 3.5) years of low-dose IS therapy. 
§At 1.5 years one patient died with severely decompensated GMG. 
The MG patients evaluated after 1 year of 'high-dose' IS 
therapy started with a mean MGS at study entry of 15.27 and 
ended with 1.79 (Table II). This is significantly different from 
the controls who scored 12.17 after 1 year of 'low-dose' therapy 
(Table II). Fifty-three per cent of the 'high-dose' IS group were 
in remission and not taking anticholinesterases, compared with 
16% of the controls. During the second 6 months the 'high-dose' 
group was receiving a mean dose of 2.43 mg/ kg azathioprine 
(SD 0.33), and only 3 of the controls were receiving 
azathioprine at a mean dose of 1.27 mg/ kg (SD 0.65, N = 3) 
(P :s; 1 x IO·') . In the 'high-dose' group the mean prednisone 
requirements were 0.23 mg/ kg (SD 0.21) in the second 
6-month treatment period compared with the controls receiving 
0.48 mg/ kg (SD 0.28, Pt·test = 0.02); 3 of the 'high-dose' subjects 
had been successfully tapered off their prednisone. 
The 10 patients on 'high-dose' IS therapy followed up for 2 
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years started with a mean MGS of 16.30 and ended with 1.22. 
The 8 controls on low-dose IS therapy scored 7.13 after an 
average of 2.7 years (Table III). Again, half of the 'high-dose' IS 
group were in remission (off anticholinesterases) compared 
with 13% of the controls. During the final 6-month treatment 
period the 'high-dose' group received a mean azathioprine 
dose of 2.33 mg/ kg (SD 0.39); 3 patients were maintained on 
azathioprine alone. Only 2 controls were receiving azathioprine 
(mean 1.15 mg/ kg, P :'> 1 x 1Q-'). The mean prednisone 
requirement for this period was 0.13 mg/ kg (SD 0.14) for the 
'high-dose' group and 0.34 mg/ kg (SD 0.30, P = 0.03) for the 
control group. One-third of the 'high-dose' group had been 
successfully weaned off prednisone. 
Scrutinising the records of a larger number of historical 
controls (N = 56) who received IS treatment between 1986 and 
1996, and within 2 years of symptoms, showed that the control 
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Table IV. Morbidity in the 'high-dose' IS group compared with 'low-dose' controls 
Hospital admissions Plasma exchange ICU admissions 
(%subjects* (N)t) (% subjects* (N)) (%subjects* (N)) 
'Low-dose' controls 
~ 1 year of IS therapy 48+ (40)§ 20'll (11)§ 30+ (24)§ 
(N = 56) 
1 - 2 yrs of IS therapy 25'j[ (15) 11 19'j[ (6) g'll (4) 11 
(N =32) 
'High-dose' IS therapy 
~ 1 year of IS therapy 6+m 6'll (1) o+ 
(N = 17) 
1 - 2 yrs of IS therapy o'll o'll o'll 
(N = 10) 
* % subjects refers to the number of patients affected by the events. 
t Events related to the time of diagnosis have been excluded. N refers to the actual number of events. 
:t Px2 < O.Dl (df = 1). 
§ Nine patients had " 2 hospital admissions, 3 had " 3 courses of P / E and 5 had " JCU admissions. 
'll Not significant. 
11 One patient died with decompensated GMG. Of the 56 original contro!s, data were only available on 32 for the evaluation period 1 - 2 years. 
remission rate was similar to that of the smaller group of 
controls (Tables II and III); at 1 and 2 years the numbers in 
remission were 3% and 11% respectively. Two controls who 
defaulted from therapy were assumed to be in remission. 
Furthermore, compared with the ' low-dose' controls, hospi tal 
and ICU admissions were significantly reduced in the 'high-
dose' IS group in the first year of therapy (Table IV). One 
control patient died after 1.5 years of therapy with severely 
decompensated active GMG and overwhelming infection. 
The 'high-dose' IS drugs were well tolerated; 1 patient 
became Cushingoid and 2 developed hypertension on 
prednisone. Three patients d eveloped transient lymphopenia 
on azathioprine doses of 2.3, 2.5 and 2.8 mg/ kg respectively, 
but blood counts stabilised on lower doses. Two patients were 
excluded from the 'high-dose' group analysis - 1 defaulted for 
2 months for socio-economic reasons and another was excl uded 
as the doctors in a secondary hospital stopped medication for 2 
months. Both these patients deteriorated transiently. 
DISCUSSION 
There are two aspects to the treatment of MG. Therapy is firstly 
directed at symptomatic management by enhancing 
neuromuscular transmission at the residual AChR (i.e. those 
receptors not yet destroyed by the autoimmune attack). 
Availability of acetylcholine at the neuromuscular junction is 
increased by anticholinesterases such as pyridostigmine 
(Mestinon) which is given orally, and neostigmine (Prostigrnin) 
which can be given by subcutaneous or intramuscular injection 
for a quicker onset of action. However, symptomatic therapy, 
whatever the dose, does not alter this immune-mediated 
disease." Anticholinesterases are therefore important while the 
patient is symptomatic, but our data suggest that by aiming to 
render the patient asymptomatic with IS therapy, the medium-
term outcome is considerably improved . 
Secondly, the autoimmune attack aga inst the AChRs must be 
immunosuppressed. As mentioned, IS therapy has already 
made a dramatic impact on the therapy of GMG; it hould no 
longer have 'grave' implications in the majority of cases, and 
the mortality rate has approached zero in the last three 
decades.U5 Before our current study the morbidity was still 
considerable, with patients unable to maintain employment or 
even to perform housework. Furthermore, after many years of 
either only symptomatic or 'low-dose' IS therapy, very few 
patients wen t into remission. 
We have demonstrated that 'high-dose' IS therapy, early in 
the evol ution of GMG, re ults in a significan t increase in the 
number of patients in remission. This is already evident within 
1 year of initiation of therapy. Paradoxically, despite significant 
immunosuppression, these patients are more resis tant to 
myasthenic decompensation from infectious disease and 
require less hospitalisation, lCU admissions and additiona l 
P /E. The treatment regimen is a lso much cheaper as the 
anticholinesteras"s (the most expensive item) is either stopped · 
in most cases, or required less frequentl y. Also, prednisone is 
not the mainstay of immunosuppression and can often be 
successfully wi thdrawn. A double-blind placebo-controlled 
trial recently published,'" albeit of a different design, found 
similar results. Patients receiving prednisolone alone or in 
combina tion with aza thioprine($ 2.5 mg/ kg), showed the 
azathioprine group to be associa ted with longer remissions and 
fewer side-effects when followed up for 3 years-'8 
Most GMG patients will need IS therapy, al though in 
occasional patients the disease is mild with easily controlled 
symptoms. However, it must be stressed that patients often 
underplay or don't mention symptoms (especially difficulty 
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with chewing, swallowing or voice changes). These individuals 
with inadequately controlled bulbar symptoms are at particular 
risk of developing frequent upper and lower respiratory tract 
infection, as well as respiratory failure. 
Most texts suggest high-dose azathioprine (2 - 3 mg/ kg) as 
an alternative immunosuppressant to steroids in the treatment 
of GMG.'·15•19 The main drawback is its long la tent period before 
drug activity (3- 6 months). Generally it is well tolerated , as 
found in our study. In rare instances an idiosyncratic reaction 
of diarrhoea and vomiting may develop,. but this was no t 
encountered among the patients in this study. ausea was no t 
a problem if the medication was taken after meals, and if 
necessary the dose was split into a twice-daily dose. Transient 
lymphopenia may occur but after cessation of azathioprine for 
a few days, it may be successfully re-introduced at a lower 
dose. 
Concern was raised in 1984 regarding an increased risk of 
cancer in patients receiving azathioprine."' The experience of 
many has been that there is no clinically significant 
carcinogenic effect of azathioprine21 ·23 although the risk may be 
increased after 10 years on high doses." 
This study may be criticised for not being more rigorous in 
its design. We decided against a case-control trial for two 
reasons- firstly, we felt tha t to withhold treatment that was 
generally advised from a control group would be unethical. 
Secondly, we anticipated small numbers of new patients to 
follow up and decided to enter them all and use the patients 
previously attending the clinic on the o ld regimen as controls. 
Although the controls were not followed in parallel to our 
study patients, they had also received IS therapy within 2 years 
of symptom onset. Further, we were able to assess some of the 
controls using the same scale (MGS) at comparable treahnent 
duration endpoints as the 'high-dose' study group. The type of 
GMG, age of onset in the controls and timing of thymectomies 
in the EOMG subgroup were also comparable to those of our 
tudy patients. Also, it is noteworthy that the control remission 
rates found in this study are similar to those of previous 
studies."~' 
In conclusion, we have shown that 'high-dose' azathioprine 
and prednisone IS therapy early in GMG result in a higher 
clinical remission rate and significantly less morbidity in those 
not in remission. Prednisone can be withdrawn slowly and 
often successfully, relatively early. There are currently no 
guidelines as to how long the high-maintenance dose of 
azathioprine should be continued for those in remission on 
azathioprine alone. Mertens and colleagues" report that 
approximately 10% of their p a tients tay in remission following 
azathiopr.ine withdrawal but do not specify after how many 
years the treatment is weaned . 
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